|
C1ORF77 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.08006961549745E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.41420241972901E-11 |
| Normal-vs-Stage2 |
6.98979999991245E-07 |
| Normal-vs-Stage3 |
2.22549978445841E-10 |
| Normal-vs-Stage4 |
7.3565999958447E-09 |
| Stage1-vs-Stage2 |
6.656600E-01 |
| Stage1-vs-Stage3 |
1.675560E-01 |
| Stage1-vs-Stage4 |
2.100000E-01 |
| Stage2-vs-Stage3 |
6.229400E-01 |
| Stage2-vs-Stage4 |
5.731800E-01 |
| Stage3-vs-Stage4 |
8.720200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.68749516769185E-13 |
| Normal-vs-AfricanAmerican |
3.862100E-03 |
| Normal-vs-Asian |
1.171470E-04 |
| Caucasian-vs-AfricanAmerican |
5.731700E-02 |
| Caucasian-vs-Asian |
2.644400E-02 |
| AfricanAmerican-vs-Asian |
8.157400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.48169953873412E-10 |
| Normal-vs-Female |
9.38504829406384E-12 |
| Male-vs-Female |
7.457200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.19619869565213E-11 |
| Normal-vs-Age(41-60Yrs) |
3.05449998627694E-09 |
| Normal-vs-Age(61-80Yrs) |
2.62829980002266E-10 |
| Normal-vs-Age(81-100Yrs) |
1.335150E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.660800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.226570E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.286400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.259800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.387400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.679800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.03760000042175E-07 |
| Classical-VS-Follicular |
1.821200E-01 |
| Classical-VS-Other |
6.485200E-01 |
| Classical-VS-Normal |
1.0373002456987E-10 |
| Tall-VS-Follicular |
3.999900E-03 |
| Tall-VS-Other |
4.724400E-02 |
| Tall-VS-Normal |
1.6286971771251E-12 |
| Follicular-VS-Other |
9.235800E-01 |
| Follicular-VS-Normal |
2.08410000368531E-08 |
| Other-VS-Normal |
4.775800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.63490015864443E-10 |
| Normal-vs-N1 |
1.51049999952413E-07 |
| N0-vs-N1 |
8.367000E-01 |
|
|
